We are live on ! Find out more
CAC

Cowen and Company Portfolio holdings

AUM $2.97B
1-Year Est. Return 105.26%
This Fund
S&P 500
This Quarter Est. Return
+10.51%
1 Year Est. Return
+105.26%
3 Year Est. Return
+120.06%
5 Year Est. Return
+670.57%
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$355M
Cap. Flow
+$316M
Cap. Flow %
26.21%
Top 10 Hldgs %
40.06%
Holding
747
New
182
Increased
169
Reduced
181
Closed
163

Top Buys

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$64M
2
MMP
Magellan Midstream Partners, L.P.
MMP
+$42.3M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$41.5M
4
PTCT icon
PTC Therapeutics
PTCT
+$39.1M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$31.8M

Top Sells

Rank Stock Value
1
SLVM icon
Sylvamo
SLVM
+$99.5M
2
KVSC
Khosla Ventures Acquisition Co. III Class A Common Stock
KVSC
+$24.5M
3
TIOA
Tio Tech A Class A Ordinary Share
TIOA
+$22.2M
4
IMVT icon
Immunovant
IMVT
+$19.4M
5
AVDL
Avadel Pharmaceuticals
AVDL
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 36.03%
2 Financials 28.77%
3 Technology 9.99%
4 Energy 5.75%
5 Consumer Discretionary 4.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVDA icon
1
NVIDIA
NVDA
$4.6T
$81.5M 6.76%
+1,927,500
New +$64M
ESTA icon
2
Establishment Labs
ESTA
$2.71B
$66.3M 5.49%
966,172
+100,000
+12% +$6.91M
RNAM
3
DELISTED
Avidity Biosciences
RNAM
$62.4M 5.17%
5,629,103
+1,036,137
+23% +$13M
PTGX icon
4
Protagonist Therapeutics
PTGX
$8.55B
$45.8M 3.79%
+1,657,551
New +$41.5M
MMP
5
DELISTED
Magellan Midstream Partners, L.P.
MMP
$45.2M 3.75%
+725,000
New +$42.3M
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$43.9M 3.64%
2,664,076
-1,068,702
-29% -$13.9M
STOK icon
7
Stoke Therapeutics
STOK
$1.84B
$39.6M 3.28%
3,721,659
+442,517
+13% +$4.71M
TARS icon
8
Tarsus Pharmaceuticals
TARS
$2.55B
$36.1M 2.99%
+1,999,383
New +$31.8M
PTCT icon
9
PTC Therapeutics
PTCT
$6.18B
$32.5M 2.7%
+799,511
New +$39.1M
AAC
10
DELISTED
Ares Acquisition Corporation
AAC
$29.9M 2.48%
2,831,626
+1,527,398
+117% +$15.9M
IMCR icon
11
Immunocore
IMCR
$1.7B
$27.6M 2.29%
460,036
+54,862
+14% +$3.13M
SMFG icon
12
Sumitomo Mitsui Financial
SMFG
$159B
$24.1M 2%
2,800,730
– –
RCKT icon
13
Rocket Pharmaceuticals
RCKT
$343M
$21.9M 1.81%
1,100,000
– –
PEGR
14
DELISTED
Project Energy Reimagined Acquisition Corp. Class A Ordinary Share
PEGR
$18.7M 1.55%
1,809,614
+309,614
+21% +$3.18M
SCPH
15
DELISTED
scPharmaceuticals
SCPH
$18.7M 1.55%
1,837,918
-969,644
-35% -$10.1M
ET icon
16
Energy Transfer Partners
ET
$69.5B
$18.2M 1.51%
1,435,000
+50,500
+4% +$640K
RRAC
17
DELISTED
Rigel Resource Acquisition Corp.
RRAC
$16.6M 1.37%
+1,547,134
New +$16.4M
HCVIU
18
DELISTED
Hennessy Capital Investment Corp. VI Unit
HCVIU
$15.4M 1.28%
1,500,000
– –
EOCW
19
DELISTED
Elliott Opportunity II Corp.
EOCW
$15.2M 1.26%
+1,463,962
New +$15.1M
INVZ icon
20
Innoviz Technologies
INVZ
$84.1M
$14.2M 1.18%
5,015,833
+319,724
+7% +$882K
MSOS icon
21
AdvisorShares Pure US Cannabis ETF
MSOS
$814M
$14.2M 1.18%
2,566,280
+998,000
+64% +$5.47M
META icon
22
Meta Platforms (Facebook)
META
$1.49T
$12.2M 1.01%
42,542
+27,430
+182% +$6.77M
DNAD
23
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$11.4M 0.95%
1,104,200
+1,050,300
+1,949% +$10.8M
COIN icon
24
Coinbase
COIN
$42.2B
$11.4M 0.95%
159,352
+25,506
+19% +$1.52M
MERC icon
25
Mercer International
MERC
$40.5M
$11.3M 0.94%
+1,400,000
New +$12.7M
1
2 3 4 5

Similar funds

CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
PWLP
Prio Wealth Limited Partnership Boston, Massachusetts $3.41B AUM 44.09% 1-Year Est. Return
FPCG
Fort Pitt Capital Group Pittsburgh, Pennsylvania $3.55B AUM 34.86% 1-Year Est. Return
SI
Scout Investments Kansas City, Missouri $3.8B AUM 45.91% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return

Cowen and Company's Q2 2023 Portfolio in Review

As of Q2 2023, Cowen and Company held 747 positions worth $1.21B, up 42% from $851M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cowen and Company deployed $316M of net new capital in Q2 2023, opening 182 new positions and adding to 169 existing holdings. Its largest new stake was NVIDIA: 1,927,500 shares worth $81.5M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 38% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $13.9M trimmed.

  • Cowen and Company's largest Q2 2023 buy was NVIDIA: 1,927,500 shares worth $81.5M.
  • Cowen and Company added most to Ares Acquisition Corporation in Q2 2023, an estimated $15.9M increase.
  • Cowen and Company's biggest Q2 2023 reduction was Avadel Pharmaceuticals, cutting an estimated $13.9M.
  • Cowen and Company fully exited Sylvamo in Q2 2023, selling an estimated $99.5M.
  • Cowen and Company's ten largest holdings make up 40% of its $1.21B portfolio in Q2 2023.
  • Cowen and Company opened 182 new positions and closed 163 in Q2 2023.
  • Cowen and Company's portfolio value rose 42% quarter-over-quarter to $1.21B.

Based on Cowen and Company's 13F filing for Q2 2023, filed 7 Aug 2023.